利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.026 秒)

    METHODS AND MATERIALs FOR ASSESSING PROSTATE CANCER THERAPIES
    4.
    发明申请
    METHODS AND MATERIALs FOR ASSESSING PROSTATE CANCER THERAPIES 审中-公开
    用于评估前列腺癌治疗的方法和材料

    公开(公告)号：WO2005060661A3

    公开(公告)日：2005-08-04

    申请号：PCT/US2004042221

    申请日：2004-12-16

    申请人： UNIV CALIFORNIA ,  SAWYERS CHARLES L ,  CHEN CHARLIE D ,  WELSBIE DEREK

    发明人： SAWYERS CHARLES L ,  CHEN CHARLIE D ,  WELSBIE DEREK

    IPC分类号： A01N43/04 ,  A61K31/70 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/574

    CPC分类号： G01N33/57434 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N2333/723 ,  G01N2500/04

    摘要： Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest (2-5 fold) increase in androgen receptor (AR) mRNA was the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides insight toward the design of novel antiandrogens.

    摘要翻译： 使用基于芯片的同基因前列腺癌异种移植模型，我们发现雄激素受体（AR）mRNA的适度（2-5倍）增加是与抗雄激素治疗发展抵抗力的唯一表达变化。 增加的AR水平通过放大来自低水平的残留配体的信号输出并改变对拮抗剂的正常反应来赋予抗雄激素抗性。 本发明提供了用于检查新的治疗方式的基于细胞的测定，并提供了对新型抗雄激素的设计的洞察。

    BIOMARKER FOR SENSITIVITY TO MTOR INHIBITOR THERAPY IN KIDNEY CANCER
    5.
    发明申请
    BIOMARKER FOR SENSITIVITY TO MTOR INHIBITOR THERAPY IN KIDNEY CANCER 审中-公开
    生物标记用于敏感性，可用于生物耐药性

    公开(公告)号：WO2006102111A3

    公开(公告)日：2006-11-30

    申请号：PCT/US2006009775

    申请日：2006-03-17

    申请人： UNIV CALIFORNIA ,  SAWYERS CHARLES L ,  THOMAS GEORGE V

    发明人： SAWYERS CHARLES L ,  THOMAS GEORGE V

    IPC分类号： G01N33/50 ,  C12Q1/68

    CPC分类号： G01N33/5091 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/178 ,  G01N2333/4703 ,  G01N2333/4704

    摘要： The invention disclosed herein provides methods for the examination and/ or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells.

    摘要翻译： 本文公开的本发明提供了用于检查和/或定量在诸如癌症的病理学中分离的生物化学途径的方法以及适于进行这些方法的试剂和试剂盒。 例如，公开了人肾癌细胞中VHL损失和mTOR抑制剂敏感性之间的相关性，表明VHL损失赋予这些细胞自主和血管生成的竞争优势。

    METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER THERAPIES AND COMPOUNDS
    7.
    发明申请
    METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER THERAPIES AND COMPOUNDS 审中-公开
    用于评估前列腺癌治疗和化合物的方法和材料

    公开(公告)号：WO2005099693A2

    公开(公告)日：2005-10-27

    申请号：PCT/US2005005529

    申请日：2005-02-23

    申请人： UNIV CALIFORNIA ,  JUNG MICHAEL E ,  OUK SAMEDY ,  SAWYERS CHARLES L ,  CHEN CHARLIE D ,  WELSBIE DEREK

    发明人： JUNG MICHAEL E ,  OUK SAMEDY ,  SAWYERS CHARLES L ,  CHEN CHARLIE D ,  WELSBIE DEREK

    IPC分类号： A61K31/426

    CPC分类号： A61K31/426

    摘要： A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides for the design of novel antiandrogen compounds.

    摘要翻译： 雄激素受体（AR）mRNA的适度（2-5倍）增加是与抗雄激素治疗发展抵抗力的唯一表达变化。 增加的AR水平通过放大来自低水平的残留配体的信号输出并改变对拮抗剂的正常反应来赋予抗雄激素抗性。 本发明提供了用于检查新的治疗方式的基于细胞的测定法，并提供了新的抗雄激素化合物的设计。